8-K: Processa Pharmaceuticals Changes Auditors Following Merger

Processa Pharmaceuticals has changed its independent auditor from BD & Company to Cherry Bekaert LLP following BD & Company's merger with Citrin Cooperman.

Summary

• Processa Pharmaceuticals' previous independent auditor, BD & Company, resigned on October 31, 2024, due to its merger with Citrin Cooperman.
• There were no disagreements between Processa and BD & Company regarding accounting principles, financial disclosures, or auditing procedures during the two most recent fiscal years and the subsequent interim period.
• BD & Company's audit reports for the fiscal years ending December 31, 2023 and 2022 did not contain any adverse opinions, disclaimers, or qualifications.
• Processa's Audit Committee approved the engagement of Cherry Bekaert LLP as the new independent auditor on November 6, 2024.
• Cherry Bekaert will serve as the auditor for the fiscal year ending December 31, 2024, and related interim periods.
• Processa did not consult with Cherry Bekaert on any accounting or auditing matters prior to their appointment.

Sentiment

Score: 7

Explanation: The document indicates a routine change of auditors due to a merger, with no apparent issues or concerns. The transition appears to be well-managed, which is a positive sign.

Positives

• The transition to a new auditor appears to be smooth, with no reported disagreements or issues with the previous auditor.
• The audit reports from the previous auditor were clean, indicating a healthy financial reporting environment.

Risks

• The change in auditors could potentially introduce some short-term uncertainty, although the transition appears to be well-managed.
• Any future disagreements with the new auditor could lead to potential issues with financial reporting.

Future Outlook

The company has appointed a new auditor for the fiscal year ending December 31, 2024, and related interim periods.

Industry Context

Changes in auditors are not uncommon, especially following mergers or acquisitions of accounting firms. This change appears to be a routine transition following the merger of BD & Company.

Comparison to Industry Standards

• The process of changing auditors is a standard practice in the industry, and the company appears to have followed the required procedures.
• The lack of disagreements with the previous auditor is a positive sign, as it indicates a healthy relationship and adherence to accounting standards.
• The appointment of Cherry Bekaert, a well-known accounting firm, is consistent with industry norms for publicly traded companies.

Stakeholder Impact

• Shareholders should be aware of the change in auditors, but the transition appears to be smooth and without any negative implications.
• The change in auditors should not have a significant impact on employees, customers, or suppliers.

Key Dates

Keywords

auditor, accounting, financial reporting, BD & Company, Cherry Bekaert, merger, audit, Processa Pharmaceuticals